Media Release
Zurich, October 16, 2025

Xlife Sciences AG Publishes 2024 ESG Report: Sustainable Value Creation as a Strategic Core

Zurich, 16th of October 2025: Xlife Sciences AG (SIX: XLS) today announced the publication of its 2024 ESG Report. The report documents the company's progress in integrating environmental, social, and governance (ESG) principles into its corporate strategy and portfolio management development. Xlife Sciences places particular emphasis on combining scientific excellence with responsible growth. The report illustrates how sustainability is embedded as a core element of the company's identity - from investment decisions to the activities of its portfolio companies in biotechnology, medical technology, technology platforms, and artificial intelligence.

Compared to the previous year, Xlife Sciences recorded significant improvements in its sustainability performance: both water consumption and indirect emissions were substantially reduced. At the same time, ESG considerations were further integrated into investment decisions and portfolio management, employee training was expanded, and collaboration with Generation Impact Global as a GRI partner was continued to further enhance transparency and international comparability.

This year's edition of the report also highlights the ongoing development of ESG structures and processes, measurable progress in energy efficiency, resource conservation, and emissions reduction, as well as the promotion of diversity, equality, and continuous education across all levels.

«*We invest in innovations that improve people's lives while taking responsibility for their ecological and social impact. The 2024 ESG Report underscores our commitment to embedding sustainable value creation in the life sciences sector over the long term*», said Désirée A. Dosch, Member of the Board of Directors, Xlife Sciences AG.

The report was prepared in accordance with the Global Reporting Initiative (GRI) standards, which provide internationally recognized guidelines for transparent and comparable sustainability reporting.

As part of its commitment to responsible action, Xlife Sciences is supporting the Cleaner, Safer Water in Cambodia Initiative in 2024 - a Gold Standard-certified climate protection program that provides rural communities with access to clean drinking water through ceramic filters. The project reduces CO_2 emissions by around 90.000 tons per year, protects forests, strengthens local businesses, and improves the living conditions of nearly two million people - an example of how Xlife Sciences combines environmental responsibility with social impact.

The full 2024 ESG Report is available for download at https://www.xlifesciences.ch/en/esg-en

Financial calendar

Annual Report 2025	28 April 2026
Annual Shareholders Meeting 2026	26 June 2026
Half-Year Report 2026	24 September 2026

Contact
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, dennis.fink@xlifesciences.ch

About Xlife Sciences AG (XLS SW)
Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development and participates in their subsequent performance. For more information, visit https://www.xlifesciences.ch/en/home

Disclaimer
Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.

Xlife Sciences AG, Talacker 35, 8001 Zurich, Switzerland, Phone +41 44 385 84 60
info@xlifesciences.ch, www.xlifesciences.ch, Commercial Register Zurich CHE-330.279.788